A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

Running, not enrolling · Phase 3

Conditions studied: Dry Eye Disease

In brief

Dry Eye Disease (DED) refers to a long-term condition that happens when there is not enough lubrication in your eyes. This can happen when your eye cannot make enough tears or if you make poor-quality tears. The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (ABBV-444) with Refresh Optive UD for 90 days in participants with Dry Eye Disease (DED. ABBV-444 is being developed for the treatment of Dry Eye Disease (DED). Participants will be placed into 1 of 2 treatment arms. Each group receives different treatment. Adult participants diagnosed with dry eye disease will be enrolled. Around 250 participants will be enrolled in the study at approximately 20 sites across the US In this study, participants first complete a 7-day run-in period using REFRESH PLUS® eye drops. Those eligible are then randomized to receive ABBV-444 eye drops or REFRESH OPTIVE® Unit Dose eye drops. Participants in both arms will receive treatment for a 90-day treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend multiple required study visits during the study at the study site. The effect of the treatment will be checked by medical assessments and questionnaires.

Key facts

Study ID: NCT07284381
Run by: AbbVie
People needed: 261
Starts: 2025-12-15
Expected to finish: 2026-08-01
Last updated by the study team: 2026-06-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Ocular Surface Disease Index (OSDI) score of ≥ 28 and ≤ 65 (based upon a 0 to 100 scale) at Screening. (Day -7) and an OSDI score of ≥ 18 and ≤ 65 (based upon a 0 to 100 scale) at Baseline (Day 1).
Three consecutive tear breakup time (TBUT) tests of ≤ 10 seconds in at least 1 eye at both the Screening (Day -7) and Baseline (Day 1) Visits.
Grade 1 to 4 (modified National Eye Institute [NEI] Grid, score range = 0 to 5) staining in at least 1 area of the cornea (5 areas examined) or conjunctiva (6 areas examined) that is related to dry eye in at least 1 eye at both Screening (Day -7) and Baseline (Day 1).
Have used an artificial tear product for dry eye disease (DED) within 6 months of Screening (Day -7) Visit.

You may not qualify if…

Participant has uncontrolled severe systemic disease that, in the assessment of the investigator, would put safety of the subject at risk through participation, or which would prevent or confound protocol-specified assessments (e.g., hypertension and diabetes, Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, immunodeficiency disease, etc.).
Participant has worn contact lenses in the last 90 days prior to the Screening (Day -7) Visit and/or participant anticipates contact lens wear during the study.
Any scheduled or planned systemic surgery or procedure during the study, which in the investigator's opinion, may impact the participant's study participation.

Where it is running

Trinity Research Group /ID# 279914 — Dothan, Alabama, United States
Arizona Eye Center - West Ray Road /ID# 267993 — Chandler, Arizona, United States
Canyon City Eyecare /ID# 267948 — Azusa, California, United States
Global Research Management /ID# 267980 — Glendale, California, United States
Lakeside Vision Center /ID# 268544 — Irvine, California, United States
Eye Research Foundation /ID# 267931 — Newport Beach, California, United States
Lee Shettle Eye and Hearing /ID# 268118 — Largo, Florida, United States
Clayton Eye Center /ID# 268097 — Morrow, Georgia, United States
Coastal Research Associates - Roswell /ID# 279915 — Roswell, Georgia, United States
Kannarr Eye Care /ID# 267979 — Pittsburg, Kansas, United States
Butchertown Clinical Trials /ID# 267887 — Louisville, Kentucky, United States
Moyes Eye Centers /ID# 267944 — Kansas City, Missouri, United States
Northern New Jersey Eye Institute /ID# 267974 — South Orange, New Jersey, United States
Rochester Ophthalmological Group - Rochester /ID# 268374 — Rochester, New York, United States
Core Inc /ID# 267946 — Shelby, North Carolina, United States
Scott and Christie and Associates /ID# 268119 — Cranberry Township, Pennsylvania, United States
Southern College of Optometry /ID# 267971 — Memphis, Tennessee, United States
Total Eye Care - Memphis /ID# 268327 — Memphis, Tennessee, United States
Advancing Vision Research - Smyrna - Stonecrest Parkway /ID# 267939 — Smyrna, Tennessee, United States
Piedmont Eye Center /ID# 267929 — Lynchburg, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.